Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.

Song DG, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ Jr.

J Hematol Oncol. 2016 Jul 20;9(1):56. doi: 10.1186/s13045-016-0285-y.

2.

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr.

Mol Ther. 2016 Nov;24(11):1987-1999. doi: 10.1038/mt.2016.149. Epub 2016 Jul 21.

3.

Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.

Xu XJ, Song DG, Poussin M, Ye Q, Sharma P, Rodríguez-García A, Tang YM, Powell DJ.

Oncotarget. 2016 Dec 13;7(50):82354-82368. doi: 10.18632/oncotarget.10510.

4.

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr.

Leukemia. 2016 Jun;30(6):1355-64. doi: 10.1038/leu.2016.35. Epub 2016 Feb 22.

5.

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.

Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ Jr.

Oncotarget. 2015 Oct 6;6(30):28911-28. doi: 10.18632/oncotarget.5029.

6.

Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.

Urbanska K, Stashwick C, Poussin M, Powell DJ Jr.

Cancer Immunol Res. 2015 Oct;3(10):1130-7. doi: 10.1158/2326-6066.CIR-15-0047. Epub 2015 Jun 25.

7.

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr.

Oncotarget. 2015 Aug 28;6(25):21533-46.

8.

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.

Lynn RC, Poussin M, Kalota A, Feng Y, Low PS, Dimitrov DS, Powell DJ Jr.

Blood. 2015 May 28;125(22):3466-76. doi: 10.1182/blood-2014-11-612721. Epub 2015 Apr 17.

9.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.

10.

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.

11.

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr.

Clin Cancer Res. 2014 Jan 1;20(1):44-55. doi: 10.1158/1078-0432.CCR-13-0945. Epub 2013 Sep 17.

12.

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr.

Cancer Res. 2012 Apr 1;72(7):1844-52. doi: 10.1158/0008-5472.CAN-11-3890. Epub 2012 Feb 7.

13.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.

14.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr.

Blood. 2012 Jan 19;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub 2011 Nov 23.

15.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.

16.

Evidence for the involvement of ActA in maturation of the Listeria monocytogenes phagosome.

Poussin MA, Goldfine H.

Cell Res. 2010 Jan;20(1):109-12. doi: 10.1038/cr.2009.142. Epub 2009 Dec 22. No abstract available.

17.

The ability of Listeria monocytogenes PI-PLC to facilitate escape from the macrophage phagosome is dependent on host PKCbeta.

Poussin MA, Leitges M, Goldfine H.

Microb Pathog. 2009 Jan;46(1):1-5. doi: 10.1016/j.micpath.2008.09.008. Epub 2008 Oct 18.

18.

Characterization of Listeria monocytogenes expressing anthrolysin O and phosphatidylinositol-specific phospholipase C from Bacillus anthracis.

Wei Z, Schnupf P, Poussin MA, Zenewicz LA, Shen H, Goldfine H.

Infect Immun. 2005 Oct;73(10):6639-46.

20.

Induction of myasthenia gravis in HLA transgenic mice by immunization with human acetylcholine receptors.

Yang H, Goluszko E, David C, Okita DK, Conti-Fine B, Chan TS, Poussin MA, Christadoss P.

Ann N Y Acad Sci. 2003 Sep;998:375-8.

PMID:
14592899
21.

B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis.

Poussin MA, Tüzün E, Goluszko E, Scott BG, Yang H, Franco JU, Christadoss P.

J Immunol. 2003 Apr 15;170(8):4389-96.

22.

Evidence for glycosylphosphatidylinositol (GPI)-anchored eosinophil-derived neurotoxin (EDN) on human granulocytes.

Debierre-Grockiego F, Desaint C, Fuentes V, Poussin M, Socié G, Azzouz N, Schwarz RT, Prin L, Gouilleux-Gruart V.

FEBS Lett. 2003 Feb 27;537(1-3):111-6.

23.
24.

Role of IL-5 during primary and secondary immune response to acetylcholine receptor.

Poussin MA, Goluszko E, Franco JU, Christadoss P.

J Neuroimmunol. 2002 Apr;125(1-2):51-8.

PMID:
11960640
25.

Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Yang H, Goluszko E, David C, Okita DK, Conti-Fine B, Chan TS, Poussin MA, Christadoss P.

J Clin Invest. 2002 Apr;109(8):1111-20.

26.

Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis.

Goluszko E, Deng C, Poussin MA, Christadoss P.

J Neuroimmunol. 2002 Jan;122(1-2):85-93.

PMID:
11777546
27.
28.

Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.

Goluszko E, Hjelmström P, Deng C, Poussin MA, Ruddle NH, Christadoss P.

J Neuroimmunol. 2001 Feb 1;113(1):109-18.

PMID:
11137582
29.
30.

Animal models of myasthenia gravis.

Christadoss P, Poussin M, Deng C.

Clin Immunol. 2000 Feb;94(2):75-87. Review. Erratum in: Clin Immunol 2000 May;95(2):170.

PMID:
10637092
31.

Capture-ELISA: a new assay for the detection of immunoglobulin M isotype antibodies using Chlamydia trachomatis antigen.

Poussin M, Fuentes V, Corbel C, Prin L, Eb F, Orfila J.

J Immunol Methods. 1997 May 12;204(1):1-12.

PMID:
9202704
32.

Immunology of non-trachomatis chlamydial infection.

Poussin M, Fuentes V, Orfila J.

Infect Dis Obstet Gynecol. 1996;4(3):122-7. No abstract available.

Supplemental Content

Loading ...
Support Center